Stocktoria
Bionano Genomics, Inc. BNGO
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2018-08-01
Bionano Genomics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M |
| R&D expense | $11.4M | $24.8M | $54.0M | $49.0M | $22.5M |
| SG&A expense | $35.1M | $51.9M | $92.8M | $88.6M | $58.5M |
| Operating income | -$33.3M | -$104.0M | -$215.2M | -$131.7M | -$77.1M |
| Interest expense | — | — | $5.1M | $298,000 | $927,000 |
| Income tax | $67,000 | $33,000 | $62,000 | $1.9M | -$5.7M |
| Net income | -$26.4M | -$112.0M | -$232.5M | -$132.6M | -$72.4M |
| EPS (diluted) | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 |
| Operating cash flow | -$16.3M | -$68.9M | -$125.2M | -$124.8M | -$71.9M |
| Cash & equivalents | $3.0M | $9.2M | $17.9M | $5.1M | $24.6M |
| Inventory | $7.8M | $13.3M | $27.6M | $29.8M | $12.4M |
| Total assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M |
| Total liabilities | $29.2M | $41.3M | $118.2M | $58.1M | $40.0M |
| Shareholders' equity | $44.4M | $35.4M | $96.2M | $249.4M | $337.1M |
Source: SEC EDGAR filings · CIK 0001411690 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.